OpGen Inc (OPGN) Upgraded to “Hold” by Zacks Investment Research
According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “
Separately, Rodman & Renshaw set a $3.30 price target on OpGen and gave the company a “buy” rating in a report on Wednesday, August 10th.
OpGen (NASDAQ:OPGN) opened at 1.61 on Wednesday. OpGen has a one year low of $1.02 and a one year high of $4.65. The stock’s market cap is $34.88 million. The stock’s 50 day moving average price is $1.66 and its 200 day moving average price is $1.61.
OpGen (NASDAQ:OPGN) last announced its earnings results on Tuesday, August 9th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by $0.09. Equities analysts predict that OpGen will post ($1.17) earnings per share for the current fiscal year.
OpGen, Inc (OpGen) is a developer of precision medicine tools. The Company uses molecular testing and bioinformatics to help guide antibiotic therapy and to assist healthcare providers to combat multi-drug resistant infections (MDROs). The Company’s lead products include the QuickFISH and PNAFISH products, which are in vitro diagnostic kits for the diagnosis and prevention of infectious diseases; the Acuitas MDRO Gene Test, which is a lab-based test that provides a profile of MDRO resistant genes from patients screened for colonization or infection, and the Acuitas Lighthouse, which is used to aid in the interpretation of MDRO diagnostic test results.
Receive News & Stock Ratings for OpGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc and related stocks with our FREE daily email newsletter.